#cognitivedecline — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #cognitivedecline, aggregated by home.social.
-
https://www.fogolf.com/1402388/%f0%9f%9a%a8-trumps-disgusting-golf-grab-gets-him-removed/ 🚨 Trump’s “Disgusting” Golf Grab GETS HIM REMOVED ##CognitiveDecline ##donaldtrump ##GolfGrab ##MedinahCountryClub ##PoliticalScandals ##PresidentialConduct ##SecurityEscort ##TotallyNormalBehavior ##TrumpRemoved ##UncheckedPower ##VeryStableGenius #accountability #Canada; #deminfluencer #Donald #DonaldTrump #DonaldTrumpGolf #golftournament #iamlorenp #lorenpiretra #lorenpiretrashow #pga #POTUS #presidentscup #tarrifs #tradewar #trump #TrumpGolf #whitehouse
-
https://www.europesays.com/ie/709128/ Childhood dementia needs recognition, family says #CognitiveDecline #dementia #DHSC #Éire #Emily #Health #IE #Ireland #MPSSociety #RareDiseases #RealChange #SanfilippoSyndrome #SavingLeni
-
Dementia: Like Too Many Browser Tabs
Witness a powerful conversation about dementia. A daughter shares her mother's heartbreaking cognitive struggles, comparing them to an overloaded browser. This podcast episode offers emotional insight and understanding of dementia's impact.
Follow @biohackingpathway for more
#DementiaAwareness #CognitiveDecline #BrainHealth #MothersLove #FamilyCaregiver #EmotionalSupport #MentalHealth #HealthCare #wellbeingjourney #wellbeingwarrior #wellnes #Caregiving
-
Dementia: Like Too Many Browser Tabs
Witness a powerful conversation about dementia. A daughter shares her mother's heartbreaking cognitive struggles, comparing them to an overloaded browser. This podcast episode offers emotional insight and understanding of dementia's impact.
Follow @biohackingpathway for more
#DementiaAwareness #CognitiveDecline #BrainHealth #MothersLove #FamilyCaregiver #EmotionalSupport #MentalHealth #HealthCare #wellbeingjourney #wellbeingwarrior #wellnes #Caregiving
-
Dementia: Like Too Many Browser Tabs
Witness a powerful conversation about dementia. A daughter shares her mother's heartbreaking cognitive struggles, comparing them to an overloaded browser. This podcast episode offers emotional insight and understanding of dementia's impact.
Follow @biohackingpathway for more
#DementiaAwareness #CognitiveDecline #BrainHealth #MothersLove #FamilyCaregiver #EmotionalSupport #MentalHealth #HealthCare #wellbeingjourney #wellbeingwarrior #wellnes #Caregiving
-
Dementia: Like Too Many Browser Tabs
Witness a powerful conversation about dementia. A daughter shares her mother's heartbreaking cognitive struggles, comparing them to an overloaded browser. This podcast episode offers emotional insight and understanding of dementia's impact.
Follow @biohackingpathway for more
#DementiaAwareness #CognitiveDecline #BrainHealth #MothersLove #FamilyCaregiver #EmotionalSupport #MentalHealth #HealthCare #wellbeingjourney #wellbeingwarrior #wellnes #Caregiving
-
Family in Canada Claims Christian Grandmother was ‘Euthanized without Consent’
The family of Brigitte Stegemann, a Canadian grandmother who passed away at age 83 in July, claims that…
#Canada #Christian #Christianbeliefs #cognitivedecline #controversy #Death #eldercare #euthanasia #Euthanized #family #grandmother #MAiDprogramme #nursinghome #scandal
https://www.europesays.com/canada/224763/ -
Family sounds alarm after 83-year-old grandma dies under Canada’s assisted-death program
This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the…
#Canada #assisteddeath #BrigitteKranendonk #BrigitteStegemann #cognitivedecline #Kranendonk #medicalassistance #Physician-assistedsuicide #Stegemann #TheDailyMail
https://www.europesays.com/canada/221556/ -
DATE: September 21, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Daily variations in salivary cortisol may predict cognitive decline in older adults
An analysis of the Chicago Health and Aging Project data found that cortisol level variations may be used to predict cognitive decline in older adults. Longitudinally, individuals with medium to high cortisol intraday variability showed slower cognitive decline whereas individuals with the highest average cortisol levels tended to show faster cognitive decline. The paper was published in JAMA Network Open.
As people grow older, their mental functioning gradually worsens. This is called age-related cognitive decline. Changes are typically seen in memory, processing speed, attention, and executive functioning, although the extent of decline varies considerably between individuals. Chronic stress may contribute to this process by repeatedly activating the hypothalamic-pituitary-adrenal axis (the neural mechanism responsible for reactions to stress) and altering the regulation of the stress hormone cortisol.
Cortisol can influence brain regions that are especially important for memory and higher-order cognition, including the hippocampus and prefrontal cortex. Persistently elevated or dysregulated cortisol has therefore been investigated as a possible contributor to poorer cognitive functioning and greater risk of neurodegenerative disease.
Aside from cortisol, other systemic processes, such as inflammation, metabolic dysfunction, and vascular health, may also affect the course of cognitive aging. Because many of the factors shaping these processes are potentially modifiable, age-related cognitive decline is increasingly studied within the broader field of dementia prevention.
Study author Ted K. S. Ng and his colleagues explored daily variations in salivary cortisol in a large and racially diverse group of older adults over an 11-year follow-up period. They chose to test saliva because it specifically measures physiologically active “free” cortisol and avoids the acute stress response caused by needle pricks during blood draws. They examined the associations between these variations and participants’ cognition, Alzheimer’s disease occurrence, and cognitive decline over time.
The study used data from the Chicago Health and Aging Project (CHAP). CHAP is an established population-based longitudinal study of aging and Alzheimer’s disease among community-dwelling older adults on the South Side of Chicago in four Chicago neighborhoods with substantial proportions of Black and White older adults. CHAP data were collected in three-year cycles, starting in 1993, and with later data collection waves conducted up to 2012.
Data used in this analysis came from 3,895 participants who provided saliva samples for the study. To be included in the analysis, they needed to have provided saliva that allowed at least one valid cortisol level assessment. Participants’ average age was 77 years. Sixty-four percent of them were women, and 64 percent were Black. Eighty-three percent of these participants provided three valid saliva samples.
From the cortisol level data derived from saliva samples (cortisol levels from three collection time points), multiple indices of daily variations in hypothalamic-pituitary-adrenal axis (HPA axis) activity were created. The HPA axis is a hormone-regulating system linking the hypothalamus, pituitary gland, and adrenal glands that controls the body’s stress response, including cortisol secretion. Its activity level reflects how strongly the body’s stress-regulation system is operating. Daily variations in its activity can provide much more nuanced information.
The participants also completed in-home interviews at three-year intervals that assessed their cognitive functioning. Additionally, clinical evaluations of a smaller group of participants explored whether they were developing Alzheimer’s disease. This was done by a neurologist who was not informed about participants’ cognitive assessment scores.
The results showed that participants with middle to high intraday variability in cortisol levels—meaning how much their cortisol levels fluctuated over the course of a single day—had higher cognitive functioning at the start of the study and slower cognitive decline. Participants with the highest intraday variability in cortisol levels also tended to have better cognitive functioning at the start but did not show slower decline. Participants with the highest average cortisol levels tended to show faster cognitive decline compared to those with the lowest levels. Their cognitive function scores at the start of the study tended to be the lowest. People whose cortisol levels stayed relatively high across the day instead of dropping normally, and people who showed the largest overall change in cortisol across the day, had lower cognitive scores at the start of the study than those with the lowest values on these patterns.
These associations did not depend on the race of participants. However, Black participants tended to have lower cortisol levels, smaller daily change, and lower intraday variability in cortisol levels.
“In this cohort study of Black and White older adults, altered diurnal [daily] cortisol patterning was associated with faster cognitive decline but not short-term AD [Alzheimer’s disease] risk. These findings support salivary cortisol as a potential early biomarker of neurocognitive aging,” the study authors concluded.
The study sheds light on the utility of cortisol as a biomarker of cognitive health in older adults. However, the study did not assess the stress levels participants perceived, so it remains unknown how much the variations in cortisol levels reflect reactions to environmental stressors and how much they reflect intrinsic physiological differences or changes in the biochemistry of the body.
The paper, “Salivary Cortisol and Cognitive Decline and Alzheimer Disease in Older Adults,” was authored by Ted K. S. Ng, Todd Beck, Yashwanth Sudhini, Robert S. Wilson, Denis A. Evans, and Kumar B. Rajan.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #SalivaryCortisol #CognitiveDecline #AgingResearch #CHAPStudy #NeurocognitiveAging #Biomarker #DementiaPrevention #AlzheimersDisease #StressBiology #CognitiveHealth
-
DATE: September 21, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Daily variations in salivary cortisol may predict cognitive decline in older adults
An analysis of the Chicago Health and Aging Project data found that cortisol level variations may be used to predict cognitive decline in older adults. Longitudinally, individuals with medium to high cortisol intraday variability showed slower cognitive decline whereas individuals with the highest average cortisol levels tended to show faster cognitive decline. The paper was published in JAMA Network Open.
As people grow older, their mental functioning gradually worsens. This is called age-related cognitive decline. Changes are typically seen in memory, processing speed, attention, and executive functioning, although the extent of decline varies considerably between individuals. Chronic stress may contribute to this process by repeatedly activating the hypothalamic-pituitary-adrenal axis (the neural mechanism responsible for reactions to stress) and altering the regulation of the stress hormone cortisol.
Cortisol can influence brain regions that are especially important for memory and higher-order cognition, including the hippocampus and prefrontal cortex. Persistently elevated or dysregulated cortisol has therefore been investigated as a possible contributor to poorer cognitive functioning and greater risk of neurodegenerative disease.
Aside from cortisol, other systemic processes, such as inflammation, metabolic dysfunction, and vascular health, may also affect the course of cognitive aging. Because many of the factors shaping these processes are potentially modifiable, age-related cognitive decline is increasingly studied within the broader field of dementia prevention.
Study author Ted K. S. Ng and his colleagues explored daily variations in salivary cortisol in a large and racially diverse group of older adults over an 11-year follow-up period. They chose to test saliva because it specifically measures physiologically active “free” cortisol and avoids the acute stress response caused by needle pricks during blood draws. They examined the associations between these variations and participants’ cognition, Alzheimer’s disease occurrence, and cognitive decline over time.
The study used data from the Chicago Health and Aging Project (CHAP). CHAP is an established population-based longitudinal study of aging and Alzheimer’s disease among community-dwelling older adults on the South Side of Chicago in four Chicago neighborhoods with substantial proportions of Black and White older adults. CHAP data were collected in three-year cycles, starting in 1993, and with later data collection waves conducted up to 2012.
Data used in this analysis came from 3,895 participants who provided saliva samples for the study. To be included in the analysis, they needed to have provided saliva that allowed at least one valid cortisol level assessment. Participants’ average age was 77 years. Sixty-four percent of them were women, and 64 percent were Black. Eighty-three percent of these participants provided three valid saliva samples.
From the cortisol level data derived from saliva samples (cortisol levels from three collection time points), multiple indices of daily variations in hypothalamic-pituitary-adrenal axis (HPA axis) activity were created. The HPA axis is a hormone-regulating system linking the hypothalamus, pituitary gland, and adrenal glands that controls the body’s stress response, including cortisol secretion. Its activity level reflects how strongly the body’s stress-regulation system is operating. Daily variations in its activity can provide much more nuanced information.
The participants also completed in-home interviews at three-year intervals that assessed their cognitive functioning. Additionally, clinical evaluations of a smaller group of participants explored whether they were developing Alzheimer’s disease. This was done by a neurologist who was not informed about participants’ cognitive assessment scores.
The results showed that participants with middle to high intraday variability in cortisol levels—meaning how much their cortisol levels fluctuated over the course of a single day—had higher cognitive functioning at the start of the study and slower cognitive decline. Participants with the highest intraday variability in cortisol levels also tended to have better cognitive functioning at the start but did not show slower decline. Participants with the highest average cortisol levels tended to show faster cognitive decline compared to those with the lowest levels. Their cognitive function scores at the start of the study tended to be the lowest. People whose cortisol levels stayed relatively high across the day instead of dropping normally, and people who showed the largest overall change in cortisol across the day, had lower cognitive scores at the start of the study than those with the lowest values on these patterns.
These associations did not depend on the race of participants. However, Black participants tended to have lower cortisol levels, smaller daily change, and lower intraday variability in cortisol levels.
“In this cohort study of Black and White older adults, altered diurnal [daily] cortisol patterning was associated with faster cognitive decline but not short-term AD [Alzheimer’s disease] risk. These findings support salivary cortisol as a potential early biomarker of neurocognitive aging,” the study authors concluded.
The study sheds light on the utility of cortisol as a biomarker of cognitive health in older adults. However, the study did not assess the stress levels participants perceived, so it remains unknown how much the variations in cortisol levels reflect reactions to environmental stressors and how much they reflect intrinsic physiological differences or changes in the biochemistry of the body.
The paper, “Salivary Cortisol and Cognitive Decline and Alzheimer Disease in Older Adults,” was authored by Ted K. S. Ng, Todd Beck, Yashwanth Sudhini, Robert S. Wilson, Denis A. Evans, and Kumar B. Rajan.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #SalivaryCortisol #CognitiveDecline #AgingResearch #CHAPStudy #NeurocognitiveAging #Biomarker #DementiaPrevention #AlzheimersDisease #StressBiology #CognitiveHealth
-
DATE: September 21, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Daily variations in salivary cortisol may predict cognitive decline in older adults
An analysis of the Chicago Health and Aging Project data found that cortisol level variations may be used to predict cognitive decline in older adults. Longitudinally, individuals with medium to high cortisol intraday variability showed slower cognitive decline whereas individuals with the highest average cortisol levels tended to show faster cognitive decline. The paper was published in JAMA Network Open.
As people grow older, their mental functioning gradually worsens. This is called age-related cognitive decline. Changes are typically seen in memory, processing speed, attention, and executive functioning, although the extent of decline varies considerably between individuals. Chronic stress may contribute to this process by repeatedly activating the hypothalamic-pituitary-adrenal axis (the neural mechanism responsible for reactions to stress) and altering the regulation of the stress hormone cortisol.
Cortisol can influence brain regions that are especially important for memory and higher-order cognition, including the hippocampus and prefrontal cortex. Persistently elevated or dysregulated cortisol has therefore been investigated as a possible contributor to poorer cognitive functioning and greater risk of neurodegenerative disease.
Aside from cortisol, other systemic processes, such as inflammation, metabolic dysfunction, and vascular health, may also affect the course of cognitive aging. Because many of the factors shaping these processes are potentially modifiable, age-related cognitive decline is increasingly studied within the broader field of dementia prevention.
Study author Ted K. S. Ng and his colleagues explored daily variations in salivary cortisol in a large and racially diverse group of older adults over an 11-year follow-up period. They chose to test saliva because it specifically measures physiologically active “free” cortisol and avoids the acute stress response caused by needle pricks during blood draws. They examined the associations between these variations and participants’ cognition, Alzheimer’s disease occurrence, and cognitive decline over time.
The study used data from the Chicago Health and Aging Project (CHAP). CHAP is an established population-based longitudinal study of aging and Alzheimer’s disease among community-dwelling older adults on the South Side of Chicago in four Chicago neighborhoods with substantial proportions of Black and White older adults. CHAP data were collected in three-year cycles, starting in 1993, and with later data collection waves conducted up to 2012.
Data used in this analysis came from 3,895 participants who provided saliva samples for the study. To be included in the analysis, they needed to have provided saliva that allowed at least one valid cortisol level assessment. Participants’ average age was 77 years. Sixty-four percent of them were women, and 64 percent were Black. Eighty-three percent of these participants provided three valid saliva samples.
From the cortisol level data derived from saliva samples (cortisol levels from three collection time points), multiple indices of daily variations in hypothalamic-pituitary-adrenal axis (HPA axis) activity were created. The HPA axis is a hormone-regulating system linking the hypothalamus, pituitary gland, and adrenal glands that controls the body’s stress response, including cortisol secretion. Its activity level reflects how strongly the body’s stress-regulation system is operating. Daily variations in its activity can provide much more nuanced information.
The participants also completed in-home interviews at three-year intervals that assessed their cognitive functioning. Additionally, clinical evaluations of a smaller group of participants explored whether they were developing Alzheimer’s disease. This was done by a neurologist who was not informed about participants’ cognitive assessment scores.
The results showed that participants with middle to high intraday variability in cortisol levels—meaning how much their cortisol levels fluctuated over the course of a single day—had higher cognitive functioning at the start of the study and slower cognitive decline. Participants with the highest intraday variability in cortisol levels also tended to have better cognitive functioning at the start but did not show slower decline. Participants with the highest average cortisol levels tended to show faster cognitive decline compared to those with the lowest levels. Their cognitive function scores at the start of the study tended to be the lowest. People whose cortisol levels stayed relatively high across the day instead of dropping normally, and people who showed the largest overall change in cortisol across the day, had lower cognitive scores at the start of the study than those with the lowest values on these patterns.
These associations did not depend on the race of participants. However, Black participants tended to have lower cortisol levels, smaller daily change, and lower intraday variability in cortisol levels.
“In this cohort study of Black and White older adults, altered diurnal [daily] cortisol patterning was associated with faster cognitive decline but not short-term AD [Alzheimer’s disease] risk. These findings support salivary cortisol as a potential early biomarker of neurocognitive aging,” the study authors concluded.
The study sheds light on the utility of cortisol as a biomarker of cognitive health in older adults. However, the study did not assess the stress levels participants perceived, so it remains unknown how much the variations in cortisol levels reflect reactions to environmental stressors and how much they reflect intrinsic physiological differences or changes in the biochemistry of the body.
The paper, “Salivary Cortisol and Cognitive Decline and Alzheimer Disease in Older Adults,” was authored by Ted K. S. Ng, Todd Beck, Yashwanth Sudhini, Robert S. Wilson, Denis A. Evans, and Kumar B. Rajan.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #SalivaryCortisol #CognitiveDecline #AgingResearch #CHAPStudy #NeurocognitiveAging #Biomarker #DementiaPrevention #AlzheimersDisease #StressBiology #CognitiveHealth
-
DATE: September 21, 2026 at 01:51PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: New Blood Thinners May Help Alzheimer’s Patients, Study Finds
Source: Science Daily - Top News
Newer blood thinners may do more than prevent strokes in people with Alzheimer's disease and atrial fibrillation. Researchers found that patients taking the blood thinners—known as non-vitamin K oral anticoagulants—showed a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could be meaningful at the population level, according to the report, which appears in European...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #NewBloodThinners #AlzheimersResearch #NonVitaminKAnticoagulants #NOACs #CognitiveDecline #StrokePrevention #AtrialFibrillation #WarfarinVsNOACs #DementiaNews #ScientificStudy
-
DATE: September 21, 2026 at 01:51PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: New Blood Thinners May Help Alzheimer’s Patients, Study Finds
Source: Science Daily - Top News
Newer blood thinners may do more than prevent strokes in people with Alzheimer's disease and atrial fibrillation. Researchers found that patients taking the blood thinners—known as non-vitamin K oral anticoagulants—showed a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could be meaningful at the population level, according to the report, which appears in European...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #NewBloodThinners #AlzheimersResearch #NonVitaminKAnticoagulants #NOACs #CognitiveDecline #StrokePrevention #AtrialFibrillation #WarfarinVsNOACs #DementiaNews #ScientificStudy
-
DATE: September 21, 2026 at 01:51PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: New Blood Thinners May Help Alzheimer’s Patients, Study Finds
Source: Science Daily - Top News
Newer blood thinners may do more than prevent strokes in people with Alzheimer's disease and atrial fibrillation. Researchers found that patients taking the blood thinners—known as non-vitamin K oral anticoagulants—showed a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could be meaningful at the population level, according to the report, which appears in European...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #NewBloodThinners #AlzheimersResearch #NonVitaminKAnticoagulants #NOACs #CognitiveDecline #StrokePrevention #AtrialFibrillation #WarfarinVsNOACs #DementiaNews #ScientificStudy
-
DATE: September 18, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Lithium supplementation does not slow cognitive decline in Alzheimer’s disease, meta-analysis finds
A recent meta-analysis evaluating the cognitive effects of lithium supplementation in older adults found that the mineral does not slow cognitive decline in individuals with Alzheimer’s disease or mild cognitive impairment. The research provides evidence that commonly prescribed forms of lithium are not effective at preserving memory and thinking skills in this population. The findings were published in the Neuroscience and Biobehavioral Reviews.
Alzheimer’s disease is a progressive condition of the brain where brain cells gradually degrade and die, leading to worsening memory, confusion, and an inability to perform daily tasks. The disease is characterized by the accumulation of harmful proteins in the brain, namely amyloid-beta plaques and tau tangles, which disrupt cell communication and cause inflammation. Before a person develops full Alzheimer’s disease, they often experience mild cognitive impairment, an intermediate stage of memory loss that is noticeable but does not completely disrupt everyday life. Finding treatments that can halt or slow this progression from early memory loss to severe dementia is a major priority in medical science.
One substance that has attracted attention as a potential treatment is lithium. Lithium is a naturally occurring mineral that is most commonly formulated as a medication, such as lithium carbonate, to stabilize mood in people with bipolar disorder. In recent years, laboratory experiments have suggested that lithium might also protect brain cells from the damage seen in Alzheimer’s disease by blocking specific enzymes that lead to protein buildup.
A series of small clinical trials and earlier pooled reviews yielded mixed evidence on whether lithium can actually slow cognitive decline in humans. For example, a 2009 clinical trial investigated whether a short course of lithium could alter disease markers and slow mental decline in patients with Alzheimer’s, but it found no major benefit.
A few years later, a 2011 clinical trial indicated that long-term, low-dose lithium treatment helped stabilize memory and thinking in patients with mild cognitive impairment. Trying to make sense of these varying outcomes, a 2015 meta-analysis combined the results of these early clinical trials, yielding intriguing but still inconclusive evidence about the mineral’s protective effects.
This conflicting background set the stage for an updated analysis of lithium’s therapeutic value in Alzheimer’s disease. The research team, led by Taro Kishi of the Fujita Health University School of Medicine, wanted to incorporate the most recent clinical trials into a single, comprehensive statistical model to see if lithium offers any reliable cognitive benefits for people with mild cognitive impairment and Alzheimer’s disease.
To explore this question, the scientists utilized a meta-analysis, which is a statistical method that pools data from multiple independent studies to identify broader trends that a single study might miss. The researchers searched major scientific databases for randomized, placebo-controlled trials that tested lithium supplementation in individuals diagnosed with mild cognitive impairment or Alzheimer’s disease. In these types of trials, one group of patients receives the active medication while another receives an inactive dummy pill, allowing researchers to isolate the effects of the drug.
The final analysis included six clinical trials with a total of 435 participants. Two of the trials focused exclusively on patients with mild cognitive impairment, while the others included patients with various stages of Alzheimer’s disease. The length of the studies varied, with some tracking patients for just 10 weeks and others following them for up to two years. The types of lithium used in these trials were mostly inorganic salts, predominantly lithium carbonate, though some used lithium sulfate or lithium gluconate.
To measure cognitive changes, the original studies used standardized tests such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Examination. These tools are questionnaires and tasks designed to evaluate memory, language, attention, and basic problem-solving skills. The research team compared the cognitive test scores of the patients who took lithium with those who took a placebo to determine if the mineral slowed their rate of mental decline.
The researchers found that lithium supplementation was not better than a placebo at preserving cognitive function. When combining the data from all six studies, the difference in cognitive test scores between the lithium group and the placebo group was not statistically significant. The patients taking lithium experienced a similar rate of memory and thinking decline as those who did not receive the treatment.
The team also looked at secondary outcomes, including behavioral symptoms like agitation and aggression, which are common in advancing Alzheimer’s disease. Once again, the results were not statistically significant; lithium did not improve behavioral symptoms better than a placebo. Similarly, the rates of people dropping out of the studies or experiencing adverse side effects were roughly equal between the lithium and placebo groups.
To ensure they were not missing specific scenarios where lithium might work, the scientists performed several subgroup analyses. They checked whether the results differed depending on the patient’s diagnosis, the length of the study, the dose of lithium, or the specific formulation used. In all of these categories, lithium consistently failed to show an advantage over the placebo.
These findings are in line with research covered by PsyPost in May 2026, which found that lithium chloride treatment reduced harmful protein activity and altered brain signaling. However, the new meta-analysis evaluated clinical cognitive outcomes in human patients rather than molecular and cellular changes in laboratory cell cultures.
The results also offer interesting context for another study covered by PsyPost in September 2025. That study, which used mouse models rather than human clinical trials, found that treatment with a specific organic salt called lithium orotate prevented harmful protein accumulation and improved memory. While those animal and cellular studies suggest lithium has biological effects on Alzheimer’s mechanisms, the new study indicates that the specific inorganic lithium salts commonly used in human clinical trials, such as lithium carbonate, do not translate into measurable cognitive benefits for human patients.
As with all research, there are some caveats to consider. The meta-analysis was based on a relatively small number of studies and a modest total of 435 participants, which limits the statistical power of the analysis. A larger pool of data might be needed to detect very subtle effects. There are also a few things to keep in mind regarding the participants themselves. In the older trials, patients with mild cognitive impairment were diagnosed based on clinical symptoms rather than modern biological markers like brain scans or spinal fluid tests. This means some participants might have had memory issues caused by conditions other than early Alzheimer’s disease.
Additionally, the patients in these trials were often taking standard anti-dementia medications alongside the lithium or placebo. The types and combinations of these medications varied across the studies, which might have influenced the outcomes. Finally, the analysis focused heavily on inorganic lithium salts like lithium carbonate and lithium sulfate. Some researchers suggest that organic salts like lithium orotate might enter brain cells more efficiently and with fewer side effects, but human clinical trials testing lithium orotate for Alzheimer’s disease are currently lacking.
The study, “Lithium for Alzheimer’s disease: Insights from a meta-analysis,” was authored by Taro Kishi, Shinji Matsunaga, Youichi Saito, and Nakao Iwata.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LithiumAlzheimersNo Benefit #AlzheimersDisease #CognitiveDecline #MildCognitiveImpairment #LithiumSupplementation #NeuroscienceResearch #ClinicalTrials #MetaAnalysis #AlzheimersTreatment #BrainHealth
-
DATE: September 18, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Lithium supplementation does not slow cognitive decline in Alzheimer’s disease, meta-analysis finds
A recent meta-analysis evaluating the cognitive effects of lithium supplementation in older adults found that the mineral does not slow cognitive decline in individuals with Alzheimer’s disease or mild cognitive impairment. The research provides evidence that commonly prescribed forms of lithium are not effective at preserving memory and thinking skills in this population. The findings were published in the Neuroscience and Biobehavioral Reviews.
Alzheimer’s disease is a progressive condition of the brain where brain cells gradually degrade and die, leading to worsening memory, confusion, and an inability to perform daily tasks. The disease is characterized by the accumulation of harmful proteins in the brain, namely amyloid-beta plaques and tau tangles, which disrupt cell communication and cause inflammation. Before a person develops full Alzheimer’s disease, they often experience mild cognitive impairment, an intermediate stage of memory loss that is noticeable but does not completely disrupt everyday life. Finding treatments that can halt or slow this progression from early memory loss to severe dementia is a major priority in medical science.
One substance that has attracted attention as a potential treatment is lithium. Lithium is a naturally occurring mineral that is most commonly formulated as a medication, such as lithium carbonate, to stabilize mood in people with bipolar disorder. In recent years, laboratory experiments have suggested that lithium might also protect brain cells from the damage seen in Alzheimer’s disease by blocking specific enzymes that lead to protein buildup.
A series of small clinical trials and earlier pooled reviews yielded mixed evidence on whether lithium can actually slow cognitive decline in humans. For example, a 2009 clinical trial investigated whether a short course of lithium could alter disease markers and slow mental decline in patients with Alzheimer’s, but it found no major benefit.
A few years later, a 2011 clinical trial indicated that long-term, low-dose lithium treatment helped stabilize memory and thinking in patients with mild cognitive impairment. Trying to make sense of these varying outcomes, a 2015 meta-analysis combined the results of these early clinical trials, yielding intriguing but still inconclusive evidence about the mineral’s protective effects.
This conflicting background set the stage for an updated analysis of lithium’s therapeutic value in Alzheimer’s disease. The research team, led by Taro Kishi of the Fujita Health University School of Medicine, wanted to incorporate the most recent clinical trials into a single, comprehensive statistical model to see if lithium offers any reliable cognitive benefits for people with mild cognitive impairment and Alzheimer’s disease.
To explore this question, the scientists utilized a meta-analysis, which is a statistical method that pools data from multiple independent studies to identify broader trends that a single study might miss. The researchers searched major scientific databases for randomized, placebo-controlled trials that tested lithium supplementation in individuals diagnosed with mild cognitive impairment or Alzheimer’s disease. In these types of trials, one group of patients receives the active medication while another receives an inactive dummy pill, allowing researchers to isolate the effects of the drug.
The final analysis included six clinical trials with a total of 435 participants. Two of the trials focused exclusively on patients with mild cognitive impairment, while the others included patients with various stages of Alzheimer’s disease. The length of the studies varied, with some tracking patients for just 10 weeks and others following them for up to two years. The types of lithium used in these trials were mostly inorganic salts, predominantly lithium carbonate, though some used lithium sulfate or lithium gluconate.
To measure cognitive changes, the original studies used standardized tests such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Examination. These tools are questionnaires and tasks designed to evaluate memory, language, attention, and basic problem-solving skills. The research team compared the cognitive test scores of the patients who took lithium with those who took a placebo to determine if the mineral slowed their rate of mental decline.
The researchers found that lithium supplementation was not better than a placebo at preserving cognitive function. When combining the data from all six studies, the difference in cognitive test scores between the lithium group and the placebo group was not statistically significant. The patients taking lithium experienced a similar rate of memory and thinking decline as those who did not receive the treatment.
The team also looked at secondary outcomes, including behavioral symptoms like agitation and aggression, which are common in advancing Alzheimer’s disease. Once again, the results were not statistically significant; lithium did not improve behavioral symptoms better than a placebo. Similarly, the rates of people dropping out of the studies or experiencing adverse side effects were roughly equal between the lithium and placebo groups.
To ensure they were not missing specific scenarios where lithium might work, the scientists performed several subgroup analyses. They checked whether the results differed depending on the patient’s diagnosis, the length of the study, the dose of lithium, or the specific formulation used. In all of these categories, lithium consistently failed to show an advantage over the placebo.
These findings are in line with research covered by PsyPost in May 2026, which found that lithium chloride treatment reduced harmful protein activity and altered brain signaling. However, the new meta-analysis evaluated clinical cognitive outcomes in human patients rather than molecular and cellular changes in laboratory cell cultures.
The results also offer interesting context for another study covered by PsyPost in September 2025. That study, which used mouse models rather than human clinical trials, found that treatment with a specific organic salt called lithium orotate prevented harmful protein accumulation and improved memory. While those animal and cellular studies suggest lithium has biological effects on Alzheimer’s mechanisms, the new study indicates that the specific inorganic lithium salts commonly used in human clinical trials, such as lithium carbonate, do not translate into measurable cognitive benefits for human patients.
As with all research, there are some caveats to consider. The meta-analysis was based on a relatively small number of studies and a modest total of 435 participants, which limits the statistical power of the analysis. A larger pool of data might be needed to detect very subtle effects. There are also a few things to keep in mind regarding the participants themselves. In the older trials, patients with mild cognitive impairment were diagnosed based on clinical symptoms rather than modern biological markers like brain scans or spinal fluid tests. This means some participants might have had memory issues caused by conditions other than early Alzheimer’s disease.
Additionally, the patients in these trials were often taking standard anti-dementia medications alongside the lithium or placebo. The types and combinations of these medications varied across the studies, which might have influenced the outcomes. Finally, the analysis focused heavily on inorganic lithium salts like lithium carbonate and lithium sulfate. Some researchers suggest that organic salts like lithium orotate might enter brain cells more efficiently and with fewer side effects, but human clinical trials testing lithium orotate for Alzheimer’s disease are currently lacking.
The study, “Lithium for Alzheimer’s disease: Insights from a meta-analysis,” was authored by Taro Kishi, Shinji Matsunaga, Youichi Saito, and Nakao Iwata.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LithiumAlzheimersNo Benefit #AlzheimersDisease #CognitiveDecline #MildCognitiveImpairment #LithiumSupplementation #NeuroscienceResearch #ClinicalTrials #MetaAnalysis #AlzheimersTreatment #BrainHealth
-
DATE: September 18, 2026 at 12:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Lithium supplementation does not slow cognitive decline in Alzheimer’s disease, meta-analysis finds
A recent meta-analysis evaluating the cognitive effects of lithium supplementation in older adults found that the mineral does not slow cognitive decline in individuals with Alzheimer’s disease or mild cognitive impairment. The research provides evidence that commonly prescribed forms of lithium are not effective at preserving memory and thinking skills in this population. The findings were published in the Neuroscience and Biobehavioral Reviews.
Alzheimer’s disease is a progressive condition of the brain where brain cells gradually degrade and die, leading to worsening memory, confusion, and an inability to perform daily tasks. The disease is characterized by the accumulation of harmful proteins in the brain, namely amyloid-beta plaques and tau tangles, which disrupt cell communication and cause inflammation. Before a person develops full Alzheimer’s disease, they often experience mild cognitive impairment, an intermediate stage of memory loss that is noticeable but does not completely disrupt everyday life. Finding treatments that can halt or slow this progression from early memory loss to severe dementia is a major priority in medical science.
One substance that has attracted attention as a potential treatment is lithium. Lithium is a naturally occurring mineral that is most commonly formulated as a medication, such as lithium carbonate, to stabilize mood in people with bipolar disorder. In recent years, laboratory experiments have suggested that lithium might also protect brain cells from the damage seen in Alzheimer’s disease by blocking specific enzymes that lead to protein buildup.
A series of small clinical trials and earlier pooled reviews yielded mixed evidence on whether lithium can actually slow cognitive decline in humans. For example, a 2009 clinical trial investigated whether a short course of lithium could alter disease markers and slow mental decline in patients with Alzheimer’s, but it found no major benefit.
A few years later, a 2011 clinical trial indicated that long-term, low-dose lithium treatment helped stabilize memory and thinking in patients with mild cognitive impairment. Trying to make sense of these varying outcomes, a 2015 meta-analysis combined the results of these early clinical trials, yielding intriguing but still inconclusive evidence about the mineral’s protective effects.
This conflicting background set the stage for an updated analysis of lithium’s therapeutic value in Alzheimer’s disease. The research team, led by Taro Kishi of the Fujita Health University School of Medicine, wanted to incorporate the most recent clinical trials into a single, comprehensive statistical model to see if lithium offers any reliable cognitive benefits for people with mild cognitive impairment and Alzheimer’s disease.
To explore this question, the scientists utilized a meta-analysis, which is a statistical method that pools data from multiple independent studies to identify broader trends that a single study might miss. The researchers searched major scientific databases for randomized, placebo-controlled trials that tested lithium supplementation in individuals diagnosed with mild cognitive impairment or Alzheimer’s disease. In these types of trials, one group of patients receives the active medication while another receives an inactive dummy pill, allowing researchers to isolate the effects of the drug.
The final analysis included six clinical trials with a total of 435 participants. Two of the trials focused exclusively on patients with mild cognitive impairment, while the others included patients with various stages of Alzheimer’s disease. The length of the studies varied, with some tracking patients for just 10 weeks and others following them for up to two years. The types of lithium used in these trials were mostly inorganic salts, predominantly lithium carbonate, though some used lithium sulfate or lithium gluconate.
To measure cognitive changes, the original studies used standardized tests such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Examination. These tools are questionnaires and tasks designed to evaluate memory, language, attention, and basic problem-solving skills. The research team compared the cognitive test scores of the patients who took lithium with those who took a placebo to determine if the mineral slowed their rate of mental decline.
The researchers found that lithium supplementation was not better than a placebo at preserving cognitive function. When combining the data from all six studies, the difference in cognitive test scores between the lithium group and the placebo group was not statistically significant. The patients taking lithium experienced a similar rate of memory and thinking decline as those who did not receive the treatment.
The team also looked at secondary outcomes, including behavioral symptoms like agitation and aggression, which are common in advancing Alzheimer’s disease. Once again, the results were not statistically significant; lithium did not improve behavioral symptoms better than a placebo. Similarly, the rates of people dropping out of the studies or experiencing adverse side effects were roughly equal between the lithium and placebo groups.
To ensure they were not missing specific scenarios where lithium might work, the scientists performed several subgroup analyses. They checked whether the results differed depending on the patient’s diagnosis, the length of the study, the dose of lithium, or the specific formulation used. In all of these categories, lithium consistently failed to show an advantage over the placebo.
These findings are in line with research covered by PsyPost in May 2026, which found that lithium chloride treatment reduced harmful protein activity and altered brain signaling. However, the new meta-analysis evaluated clinical cognitive outcomes in human patients rather than molecular and cellular changes in laboratory cell cultures.
The results also offer interesting context for another study covered by PsyPost in September 2025. That study, which used mouse models rather than human clinical trials, found that treatment with a specific organic salt called lithium orotate prevented harmful protein accumulation and improved memory. While those animal and cellular studies suggest lithium has biological effects on Alzheimer’s mechanisms, the new study indicates that the specific inorganic lithium salts commonly used in human clinical trials, such as lithium carbonate, do not translate into measurable cognitive benefits for human patients.
As with all research, there are some caveats to consider. The meta-analysis was based on a relatively small number of studies and a modest total of 435 participants, which limits the statistical power of the analysis. A larger pool of data might be needed to detect very subtle effects. There are also a few things to keep in mind regarding the participants themselves. In the older trials, patients with mild cognitive impairment were diagnosed based on clinical symptoms rather than modern biological markers like brain scans or spinal fluid tests. This means some participants might have had memory issues caused by conditions other than early Alzheimer’s disease.
Additionally, the patients in these trials were often taking standard anti-dementia medications alongside the lithium or placebo. The types and combinations of these medications varied across the studies, which might have influenced the outcomes. Finally, the analysis focused heavily on inorganic lithium salts like lithium carbonate and lithium sulfate. Some researchers suggest that organic salts like lithium orotate might enter brain cells more efficiently and with fewer side effects, but human clinical trials testing lithium orotate for Alzheimer’s disease are currently lacking.
The study, “Lithium for Alzheimer’s disease: Insights from a meta-analysis,” was authored by Taro Kishi, Shinji Matsunaga, Youichi Saito, and Nakao Iwata.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LithiumAlzheimersNo Benefit #AlzheimersDisease #CognitiveDecline #MildCognitiveImpairment #LithiumSupplementation #NeuroscienceResearch #ClinicalTrials #MetaAnalysis #AlzheimersTreatment #BrainHealth
-
DATE: September 18, 2026 at 05:48AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: These blood thinners may have an unexpected benefit for Alzheimer’s patients
URL: https://www.sciencedaily.com/releases/2026/09/260917003732.htm
Newer blood thinners may do more than prevent strokes in people with Alzheimer’s disease and atrial fibrillation. Researchers found that patients taking NOACs experienced a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could add up over time.
URL: https://www.sciencedaily.com/releases/2026/09/260917003732.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersResearch #BloodThinners #NOACs #WarfarinAlternative #CognitiveDecline #AtrialFibrillation #StrokePrevention #AlzheimersTherapy #NeurologyNews #MedicalBreakthroughs
-
DATE: September 18, 2026 at 05:48AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: These blood thinners may have an unexpected benefit for Alzheimer’s patients
URL: https://www.sciencedaily.com/releases/2026/09/260917003732.htm
Newer blood thinners may do more than prevent strokes in people with Alzheimer’s disease and atrial fibrillation. Researchers found that patients taking NOACs experienced a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could add up over time.
URL: https://www.sciencedaily.com/releases/2026/09/260917003732.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersResearch #BloodThinners #NOACs #WarfarinAlternative #CognitiveDecline #AtrialFibrillation #StrokePrevention #AlzheimersTherapy #NeurologyNews #MedicalBreakthroughs
-
DATE: September 18, 2026 at 05:48AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: These blood thinners may have an unexpected benefit for Alzheimer’s patients
URL: https://www.sciencedaily.com/releases/2026/09/260917003732.htm
Newer blood thinners may do more than prevent strokes in people with Alzheimer’s disease and atrial fibrillation. Researchers found that patients taking NOACs experienced a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could add up over time.
URL: https://www.sciencedaily.com/releases/2026/09/260917003732.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersResearch #BloodThinners #NOACs #WarfarinAlternative #CognitiveDecline #AtrialFibrillation #StrokePrevention #AlzheimersTherapy #NeurologyNews #MedicalBreakthroughs
-
https://www.europesays.com/ie/679634/ 7 brain-healthy foods Indians should eat more often to support memory and ageing #Alcohol #Alzheimer'sDisease #BrainHealth #BrainSuperfood #BrainBoostingFoods #choline #CognitiveDecline #DementiaPrevention #DietForBrain #Éire #fish #Fruits #Health #HealthyEating #HealthyLifestyle #IE #IndianDiet #Ireland #legumes #MediterraneanDiet #MemoryImprovement #MindDiet #Nutrition #nuts #Omega3 #ProcessedFoods #Sugar #Vegetables #VitaminB12 #VitaminD #WholeGrains
-
DATE: August 8, 2026 at 12:08AM
SOURCE: AMERICAN PSYCHOLOGICAL ASSOCIATIONTITLE: Is watching too much TV bad for your brain? Possibly
URL: https://www.cnn.com/2026/08/08/health/television-brain-dementia-sedentary-health-wellness
Researchers found that people who reported watching television more often in midlife had smaller brain volumes decades later in areas involved in language and thinking.
URL: https://www.cnn.com/2026/08/08/health/television-brain-dementia-sedentary-health-wellness
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #TVtime #BrainHealth #MidlifeWellness #CognitiveDecline #BrainVolume #HealthyHabits #MediaConsumption #Neurofitness #LanguageCenters #SleepAndBrain
-
DATE: August 8, 2026 at 12:08AM
SOURCE: AMERICAN PSYCHOLOGICAL ASSOCIATIONTITLE: Is watching too much TV bad for your brain? Possibly
URL: https://www.cnn.com/2026/08/08/health/television-brain-dementia-sedentary-health-wellness
Researchers found that people who reported watching television more often in midlife had smaller brain volumes decades later in areas involved in language and thinking.
URL: https://www.cnn.com/2026/08/08/health/television-brain-dementia-sedentary-health-wellness
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #TVtime #BrainHealth #MidlifeWellness #CognitiveDecline #BrainVolume #HealthyHabits #MediaConsumption #Neurofitness #LanguageCenters #SleepAndBrain
-
DATE: August 8, 2026 at 12:08AM
SOURCE: AMERICAN PSYCHOLOGICAL ASSOCIATIONTITLE: Is watching too much TV bad for your brain? Possibly
URL: https://www.cnn.com/2026/08/08/health/television-brain-dementia-sedentary-health-wellness
Researchers found that people who reported watching television more often in midlife had smaller brain volumes decades later in areas involved in language and thinking.
URL: https://www.cnn.com/2026/08/08/health/television-brain-dementia-sedentary-health-wellness
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #TVtime #BrainHealth #MidlifeWellness #CognitiveDecline #BrainVolume #HealthyHabits #MediaConsumption #Neurofitness #LanguageCenters #SleepAndBrain
-
https://www.europesays.com/ie/671219/ FDA approves new Alzheimer’s blood test that family doctors can order #Alzheimer #Alzheimer's #Alzheimer'sBloodTest #Alzheimer'sTest #AmyloidPlaques #Biomarker #BloodBiomarker #BloodTest #CliffordSegil #CognitiveDecline #diagnosis #disease #Éire #ElecsysPTau217 #FamilyDoctor #fda #Health #HealthCare #Healthcare #IE #Ireland #ldnd #ManishaParulekar #NewTest #patient #People #physician #PrimaryCareDoctor #pTau217 #Roche #symptom
-
DATE: September 2, 2026 at 10:32AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: Money problems may age your brain faster
URL: https://www.sciencedaily.com/releases/2026/08/260831015154.htm
Persistent financial hardship in early and middle adulthood was linked to poorer thinking skills by the 50s and more signs of brain aging later in life. Researchers say years of chronic stress and financial worry may gradually take a toll on the brain.
URL: https://www.sciencedaily.com/releases/2026/08/260831015154.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #MoneyProblems #FinancialHardship #BrainAging #CognitiveDecline # StressAndHealth #MentalHealthAwareness #HealthyAging #BrainHealth #FinancialStress #AgingBrain
-
DATE: September 2, 2026 at 10:32AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: Money problems may age your brain faster
URL: https://www.sciencedaily.com/releases/2026/08/260831015154.htm
Persistent financial hardship in early and middle adulthood was linked to poorer thinking skills by the 50s and more signs of brain aging later in life. Researchers say years of chronic stress and financial worry may gradually take a toll on the brain.
URL: https://www.sciencedaily.com/releases/2026/08/260831015154.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #MoneyProblems #FinancialHardship #BrainAging #CognitiveDecline # StressAndHealth #MentalHealthAwareness #HealthyAging #BrainHealth #FinancialStress #AgingBrain
-
DATE: September 2, 2026 at 10:32AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: Money problems may age your brain faster
URL: https://www.sciencedaily.com/releases/2026/08/260831015154.htm
Persistent financial hardship in early and middle adulthood was linked to poorer thinking skills by the 50s and more signs of brain aging later in life. Researchers say years of chronic stress and financial worry may gradually take a toll on the brain.
URL: https://www.sciencedaily.com/releases/2026/08/260831015154.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #MoneyProblems #FinancialHardship #BrainAging #CognitiveDecline # StressAndHealth #MentalHealthAwareness #HealthyAging #BrainHealth #FinancialStress #AgingBrain
-
AI is creating unwanted social behaviour leading to cognitive decline. We don't have to accept this.
-
AI is creating unwanted social behaviour leading to cognitive decline. We don't have to accept this.
-
AI is creating unwanted social behaviour leading to cognitive decline. We don't have to accept this.
-
AI is creating unwanted social behaviour leading to cognitive decline. We don't have to accept this.
-
https://www.europesays.com/ie/661891/ Older married couples demonstrate domain-specific cognitive concordance #Cognition #CognitiveDecline #CognitiveFunction #CoupleBased #dementia #Éire #IE #Ireland #mmse #neurology #Technology
-
https://www.europesays.com/ch/119786/ Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test #Alzheimer’sTesting #Alzheimer'sDisease #BloodTest #CognitiveDecline #EliLilly #HealthcareProfessionals #HealthcareProviders #QuestDiagnostics #Roche
-
https://www.europesays.com/ch/119742/ FDA Clears Roche Elecsys pTau217 Blood Test for Alzheimer’s Detection #Alzheimeru2019sDisease #AmyloidPathology #biomarkers #BloodTest #ClinicalDiagnostics #CognitiveDecline #DiagnosticAssays #Elecsys #EliLilly #FDAClearance #LabInstrumentation #LaboratoryTesting #pTau217 #Roche
-
https://www.europesays.com/ie/646350/ Your Heart & Your Brain Are Craving More Of This Under-Consumed Nutrient #Alzheimer'sDisease #CognitiveDecline #Éire #EPAAndDHA #FattyFish #Health #HealthyAging #HeartDisease #IE #Ireland #MildCognitiveImpairment #Nutrition #Omega3FattyAcids #Omega3s
-
#StrawberryBenefits #CognitiveHealth #BrainBoost #healthyhabits #biohackingsecrets #wellnesscoach #SuperfoodStrawberries #biohacker #HealthyAging #healthtips #strawberries #brainhealth #cognitivedecline #depression #healthyfoods #nutritiontips #ellagicacid #anthocyanins #superfoods #eathealthy https://mastodon.social/@biohackingpathway/117098567733511456
-
https://www.europesays.com/ie/615827/ Community Gatherings Halve Cognitive Disability Risk in Older Adults #BrainResearch #Cognition #CognitiveDecline #Éire #Health #IE #Ireland #neurobiology #Neuroscience #OsakaMetropolitanUniversity #SocialNeuroscience
-
"Let's Stay Human" - by Caitlin Johnstone
https://www.caitlinjohnst.one/p/lets-stay-human
> The product they are selling us is not the chatbot itself. The actual product they’re selling is freedom from cognitive and emotional discomfort. From the discomfort of learning new skills. From the discomfort of personal growth. From the discomfort of taking risks. From the discomfort of pushing past that intimidating blank page to get something written. From the discomfort of having to think about other people and consider their interests and feelings. From the discomfort of having to interact with other humans and maybe say the wrong thing sometimes. From the discomfort of leaping into the unknown.
> But all the best things in life sit on the other side of discomfort. Love. Romance. Intimacy. Art. Creativity. Growth. Healing. Rising beyond our limitations. Liberating ourselves from the illusion of the ego. They all require us to push through discomfort to the treasure on the other side. An aversion to discomfort is an aversion to a fulfilling human life on this planet.
#collapse #AI #SamAltman #Decadence #LateStageCapitalism #degeneration #CognitiveAtrophy #CognitiveDecline #Dehumanization -
"Let's Stay Human" - by Caitlin Johnstone
https://www.caitlinjohnst.one/p/lets-stay-human
> The product they are selling us is not the chatbot itself. The actual product they’re selling is freedom from cognitive and emotional discomfort. From the discomfort of learning new skills. From the discomfort of personal growth. From the discomfort of taking risks. From the discomfort of pushing past that intimidating blank page to get something written. From the discomfort of having to think about other people and consider their interests and feelings. From the discomfort of having to interact with other humans and maybe say the wrong thing sometimes. From the discomfort of leaping into the unknown.
> But all the best things in life sit on the other side of discomfort. Love. Romance. Intimacy. Art. Creativity. Growth. Healing. Rising beyond our limitations. Liberating ourselves from the illusion of the ego. They all require us to push through discomfort to the treasure on the other side. An aversion to discomfort is an aversion to a fulfilling human life on this planet.
#collapse #AI #SamAltman #Decadence #LateStageCapitalism #degeneration #CognitiveAtrophy #CognitiveDecline #Dehumanization -
"Let's Stay Human" - by Caitlin Johnstone
https://www.caitlinjohnst.one/p/lets-stay-human
> The product they are selling us is not the chatbot itself. The actual product they’re selling is freedom from cognitive and emotional discomfort. From the discomfort of learning new skills. From the discomfort of personal growth. From the discomfort of taking risks. From the discomfort of pushing past that intimidating blank page to get something written. From the discomfort of having to think about other people and consider their interests and feelings. From the discomfort of having to interact with other humans and maybe say the wrong thing sometimes. From the discomfort of leaping into the unknown.
> But all the best things in life sit on the other side of discomfort. Love. Romance. Intimacy. Art. Creativity. Growth. Healing. Rising beyond our limitations. Liberating ourselves from the illusion of the ego. They all require us to push through discomfort to the treasure on the other side. An aversion to discomfort is an aversion to a fulfilling human life on this planet.
#collapse #AI #SamAltman #Decadence #LateStageCapitalism #degeneration #CognitiveAtrophy #CognitiveDecline #Dehumanization -
"Let's Stay Human" - by Caitlin Johnstone
https://www.caitlinjohnst.one/p/lets-stay-human
> The product they are selling us is not the chatbot itself. The actual product they’re selling is freedom from cognitive and emotional discomfort. From the discomfort of learning new skills. From the discomfort of personal growth. From the discomfort of taking risks. From the discomfort of pushing past that intimidating blank page to get something written. From the discomfort of having to think about other people and consider their interests and feelings. From the discomfort of having to interact with other humans and maybe say the wrong thing sometimes. From the discomfort of leaping into the unknown.
> But all the best things in life sit on the other side of discomfort. Love. Romance. Intimacy. Art. Creativity. Growth. Healing. Rising beyond our limitations. Liberating ourselves from the illusion of the ego. They all require us to push through discomfort to the treasure on the other side. An aversion to discomfort is an aversion to a fulfilling human life on this planet.
#collapse #AI #SamAltman #Decadence #LateStageCapitalism #degeneration #CognitiveAtrophy #CognitiveDecline #Dehumanization -
Experts Warn of Cognitive Decline in Trump Amid Health Concerns
📰 Original title: Trump's 'twitches and glitches' alarm expert amid fresh health concerns
🤖 IA: It's clickbait ⚠️
👥 Users: It's clickbait ⚠️View full AI summary https://en.killbait.com/experts-warn-of-cognitive-decline-in-trump-amid-health-concerns.html?utm_source=mastodon_world&utm_medium=social&utm_campaign=killbait.mastodon_world
#politics #cognitivedecline #politicalhealth #neurologicalconcerns
-
Experts Warn of Cognitive Decline in Trump Amid Health Concerns
📰 Original title: Trump's 'twitches and glitches' alarm expert amid fresh health concerns
🤖 IA: It's clickbait ⚠️
👥 Users: It's clickbait ⚠️View full AI summary https://en.killbait.com/experts-warn-of-cognitive-decline-in-trump-amid-health-concerns.html?utm_source=mastodon_world&utm_medium=social&utm_campaign=killbait.mastodon_world
#politics #cognitivedecline #politicalhealth #neurologicalconcerns
-
How the Vagus Nerve Promotes Healthy Cognition via Acetylcholine Signaling
-
How the Vagus Nerve Promotes Healthy Cognition via Acetylcholine Signaling
-
How the Vagus Nerve Promotes Healthy Cognition via Acetylcholine Signaling
-
How the Vagus Nerve Promotes Healthy Cognition via Acetylcholine Signaling
-
The actual paper is from 2025:
"Association Between Consumption of Low- and No-Calorie Artificial Sweeteners and Cognitive Decline: An 8-Year Prospective Study", by Natalia Gomes Gonçalves et al.2 2025
https://www.neurology.org/doi/full/10.1212/WNL.0000000000214023Conducted in Brazil:
"We conducted a longitudinal observational study using data from civil servants aged 35+ years at baseline who were enrolled in the Brazilian Longitudinal Study of Adult Health and evaluated across 3 study waves (2008–10, 2012–14, and 2017–19)."
"Consumption of aspartame, saccharin, acesulfame k, erythritol, sorbitol, and xylitol was associated with a faster decline in global cognition, particularly in memory and verbal fluency domains."
-
The actual paper is from 2025:
"Association Between Consumption of Low- and No-Calorie Artificial Sweeteners and Cognitive Decline: An 8-Year Prospective Study", by Natalia Gomes Gonçalves et al.2 2025
https://www.neurology.org/doi/full/10.1212/WNL.0000000000214023Conducted in Brazil:
"We conducted a longitudinal observational study using data from civil servants aged 35+ years at baseline who were enrolled in the Brazilian Longitudinal Study of Adult Health and evaluated across 3 study waves (2008–10, 2012–14, and 2017–19)."
"Consumption of aspartame, saccharin, acesulfame k, erythritol, sorbitol, and xylitol was associated with a faster decline in global cognition, particularly in memory and verbal fluency domains."
-
The actual paper is from 2025:
"Association Between Consumption of Low- and No-Calorie Artificial Sweeteners and Cognitive Decline: An 8-Year Prospective Study", by Natalia Gomes Gonçalves et al.2 2025
https://www.neurology.org/doi/full/10.1212/WNL.0000000000214023Conducted in Brazil:
"We conducted a longitudinal observational study using data from civil servants aged 35+ years at baseline who were enrolled in the Brazilian Longitudinal Study of Adult Health and evaluated across 3 study waves (2008–10, 2012–14, and 2017–19)."
"Consumption of aspartame, saccharin, acesulfame k, erythritol, sorbitol, and xylitol was associated with a faster decline in global cognition, particularly in memory and verbal fluency domains."
-
The actual paper is from 2025:
"Association Between Consumption of Low- and No-Calorie Artificial Sweeteners and Cognitive Decline: An 8-Year Prospective Study", by Natalia Gomes Gonçalves et al.2 2025
https://www.neurology.org/doi/full/10.1212/WNL.0000000000214023Conducted in Brazil:
"We conducted a longitudinal observational study using data from civil servants aged 35+ years at baseline who were enrolled in the Brazilian Longitudinal Study of Adult Health and evaluated across 3 study waves (2008–10, 2012–14, and 2017–19)."
"Consumption of aspartame, saccharin, acesulfame k, erythritol, sorbitol, and xylitol was associated with a faster decline in global cognition, particularly in memory and verbal fluency domains."
-
Common Digestive Drug May Help Ease Depression and Brain Fog
Many people recover from depression but continue to struggle with lingering symptoms such as memory problems, poor concentration…
#NewsBeep #News #Health #Brain #cognition #cognitivedecline #depression #digestivecondition #digestivedrug #GB #guthealth #laxatives #Memory #Mentalhealth #study #symptoms #UK #UnitedKingdom
https://www.newsbeep.com/uk/699994/ -
https://www.europesays.com/ie/592762/ New Alzheimer’s blood test predicts who is likely to develop dementia in 5 to 10 years #Alzheimer'sDisease #Alzheimer'sAssociation #AmericanMedicalAssociation #BloodTest #BloodTests #CognitiveDecline #dementia #Éire #Health #IE #Ireland #MemoryProblems #NoticeableSymptoms #OlderAdults
-
@ponderingpolitics.bsky.social host #JessiahEberlin joins #BrianShapiro to break down Trump’s ALARMING election speech, apparent #cognitivedecline, #ICEviolence, MAGA media lies, #NickShirley, #JackPosobiec, and the growing threat to the 2026 #midterms and American democracy
youtu.be/TgxX82e8l70?...
Pondering Politics Very Own Je... -
@ponderingpolitics.bsky.social host #JessiahEberlin joins #BrianShapiro to break down Trump’s ALARMING election speech, apparent #cognitivedecline, #ICEviolence, MAGA media lies, #NickShirley, #JackPosobiec, and the growing threat to the 2026 #midterms and American democracy
youtu.be/TgxX82e8l70?...
Pondering Politics Very Own Je... -
@ponderingpolitics.bsky.social host #JessiahEberlin joins #BrianShapiro to break down Trump’s ALARMING election speech, apparent #cognitivedecline, #ICEviolence, MAGA media lies, #NickShirley, #JackPosobiec, and the growing threat to the 2026 #midterms and American democracy
youtu.be/TgxX82e8l70?...
Pondering Politics Very Own Je... -
@ponderingpolitics.bsky.social host #JessiahEberlin joins #BrianShapiro to break down Trump’s ALARMING election speech, apparent #cognitivedecline, #ICEviolence, MAGA media lies, #NickShirley, #JackPosobiec, and the growing threat to the 2026 #midterms and American democracy
youtu.be/TgxX82e8l70?...
Pondering Politics Very Own Je... -
Samsung Expands Into Medical Care With Galaxy Watch
A clinical trial participant wears a Galaxy Watch to measure biometric signal data. Photo courtesy of Samsung Electronics…
#EuropeSays #Korea #KR #SamsungElectronics #AIhealthcare #cognitivedecline #dementiaresearch #GalaxyUnpacked2026 #GalaxyWatch9 #NeuroscapeUCSF #Samsung #SamsungHealth
https://www.europesays.com/korea/83311/ -
@mike_bowler Well, that explains a lot!